The global single-use bioprocessing market size was valued at USD 9.71 billion in 2017 and is projected to expand at a CAGR of 13.6% during the forecast period. The scope of the market can be also defined as biopharmaceutical manufacturing using single-use technology (SUT). SUT has supplanted a significant portion of the conventional biopharmaceutical production process with disposable equipment and this trend continues to surge.
This shift of the biopharmaceutical industry from traditional stainless-steel bioprocessing equipment to disposables is majorly influenced by proven economic and operational benefits of single-use bioprocessing engineering. Key advantages associated with SUT include reduced risk of cross-contamination, lower capital expenditure, and flexibility to fulfill changing consumer needs.
In the current scenario, biopharmaceutical producers are embracing the trend of disposables. This is due to emergence of SUTs as a widely acceptable choice among contract manufacturing organizations (CMOs). This technology is expected to witness surging profit in the coming years with a growing CMO base for biopharmaceutical production.
Rising demand for biologics and biosimilars has raised the pressure to reduce overall production cost while maintaining product quality. This has helped disposable solutions gain ground for bioproduction. This is mainly because SUTs are known to significantly reduce operation and manufacturing costs.
At present, the main goal of biomanufacturers is rapid launch and commercialization of biopharmaceuticals. This has led to growing interest in disposables for bioproduction within the bioprocessing industry.
Rising competition among single-use manufacturers is anticipated to drive significant product development, such as provision of single-use bioreactors with large working volume and capacity. The fact that major vendors are acquiring startups involved in manufacturing disposable equipment supports rising adoption and integration of single-use bioreactors (SUBs). Companies are also making enormous investments in upgrading existing single-use system (SUS) portfolios.
However, one of the issues cited by manufacturers for not incorporating SUSs in their manufacturing plants is concerns pertaining to leachables and extractables. Moreover, implementation of this system in downstream processing, in particular for chromatography-based processing, is still a hurdle due to cost reasons.
Simple and peripheral elements are estimated to have generated the highest revenue in 2017. This is mainly due to highest penetration of tubings and filters, coupled with extensive usage of these products.
Bags and containers also account for a significant share in the simple and peripheral elements segment owing to the fact that disposable technology has grown to encompass large bags equipped with connectors, ports, and automation.
Continuous innovations in SUBs with respect to scale and capacity are likely to drive the apparatus and plant segment to be a lucrative source of revenue. For instance, in November 2015, ABEC introduced the world’s largest SUB with a total volume of 4,300 L and working volume of 3,500 L. These innovations are stimulated by growing adoption of disposables by biomanufacturers seeking flexible manufacturing options.
By workflow, the single-use bioprocessing market is segmented into upstream, downstream, and fermentation. Most of the progress in single-use biomanufacturing and consequent adoption is witnessed in upstream processing. This has resulted in the highest penetration of disposables in upstream bioprocessing, thereby allowing this segment to account for the largest revenue share in 2017.
At present, usage of disposables in downstream processing is not as significant as it is in upstream processing due to cost constraints. For example, in case of chromatography systems, end users have to amortize the cost of resins through clean-and-reuse programs.
Biopharmaceutical manufacturers, particularly CMOs, held the largest share in 2017 owing to the commercial success of biologics and biosimilars and rise in outsourced production. Expanding budgets of CMOs for implementation of this technology have been also supported segment growth. Moreover, CMOs are engaged in expansion of their biomanufacturing facilities by installing SUBs of various scales, which is anticipated to majorly impact future progress.
In-house biomanufacturers accounted for a relatively smaller share in 2017 as many established stainless-steel facilities are already in place. Budget constraints for small players and start-ups are expected to generate immense growth opportunities for this segment owing to the fact that disposables are relatively less expensive.
North America is known for its in-house biopharmaceutical manufacturing facilities, which has bolstered the adoption of disposables in the region. This has allowed it to account for the dominant share with respect to revenue. A well-established bioprocessing landscape in this region has also contributed to its significant share.
With rising potential for biopharmaceutical growth, Asia Pacific is projected to witness the fastest YoY growth. Business dynamics for SUTs in this region is different from those in developed countries, characterized by lower labor costs, biogeneric products, and low operating costs.
Some of the key participants in the market are General Electric Company (GE Healthcare); Eppendorf AG; Sartorius AG; Rentschler Biopharma SE; Corning Incorporated; ThermoFisher Scientific; Pall Corporation; Merck KGaA; Kühner AG; JM BIOCONNECT; Infors AG; Lonza; Entegris, Inc.; Meissner Filtration Products, Inc.; and PBS Biotech, Inc.
Growing interest of major biopharmaceutical companies in SUTs has encouraged these entities to undertake various business endeavors to maintain a competitive edge in the market. These include acquisition of emerging/small single-use suppliers, portfolio development, regional expansions, and strengthening distribution networks.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2018 - 2025
Revenue in USD Billion and CAGR from 2018 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, France, China, India, Japan, South Korea, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global single-use bioprocessing market report on the basis of product, workflow, end use, and region:
Product Outlook (Revenue, USD Billion, 2014 - 2025)
Apparatus & Plants
Up to 1000L
Above 1000L to 2000L
Mixing, Storage, & Filling Systems
Simple & Peripheral Elements
Bags & Containers
Tubing, Filters, Connectors, & Transfer Systems
Probes & Sensors
Cell Culture System
Workflow Outlook (Revenue, USD Billion, 2014 - 2025)
End-use Outlook (Revenue, USD Billion, 2014 - 2025)
CMOs & CROs
Academic & Clinical Research Institutes
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."